Senior Director
Celldex Therapeutics
Senior Director
Celldex Therapeutics
Develops antibody-based therapies targeting inflammatory diseases
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. We have built a culture where innovative and talented people thrive—focusing a significant effort on attracting and retaining passionate and motivated employees who want to play a role in helping people with serious health conditions and who see this effort as personally rewarding. In our highly entrepreneurial environment, employees are empowered and the opportunity for professional development occurs every day.
As we prepare for potential commercialization, including our lead asset barzolvolimab, we are building a world-class Medical Affairs organization to support late-stage development and launch. Our culture is entrepreneurial, fast-moving, and deeply mission-driven—where passionate individuals can make a meaningful impact.
The Senior Director, Medical Evidence Generation, Immunology will serve as a strategic leader within Medical Affairs & Evidence Generation responsible for the development and execution of integrated evidence generation strategies and plans (i.e., IEP) supporting Celldex’s immunology portfolio. This individual will partner cross-functionally within Medical Affairs & Evidence Generation (incl. HEOR), Clinical Development, Clinical Science, Biostatistics, Regulatory, Market Access, Commercial, and external scientific experts to identify evidence gaps and drive the generation of clinically meaningful, scientifically rigorous, and impactful evidence supporting Celldex programs across the product lifecycle.
This role will lead evidence generation strategies, provide strategic oversight, and co-lead initiatives including post-marketing Ph3b/Ph4 studies in collaboration with Clinical Sciences & Clinical Development, Investigator Initiated ResearchStudies (IIRs), collaborative research efforts, real-world evidence (RWE) initiatives, outcomes research, and integrated evidence planning activities. The individual will play a key role in shaping evidence strategies supporting late-stage development, launch readiness, lifecycle management, and future commercialization activities across Celldex’s immunology pipeline.
The ideal candidate will bring strong scientific and strategic expertise in evidence generation, clinical research, Medical Affairs, and RWE studies, along with the ability to operate effectively within a highly collaborative, matrixed biotechnology environment.
Develops antibody-based therapies targeting inflammatory diseases
Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.
Explore more opportunities at Celldex Therapeutics